Cargando…

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease

BACKGROUND: Clinicians often utilize off-label dose escalation of ustekinumab (UST) in Crohn’s disease (CD) patients with disease refractory to standard dosing. Previous studies report mixed results with dose escalation of UST. METHODS: A retrospective observational study of 143 adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haider, Syedreza A., Yadav, Abhijeet, Perry, Courtney, Su, Leon, Akanbi, Olalekan, Kudaravalli, Praneeth, Tripathi, Nishant, Hashim, Mahmoud A., Abdelsalam, Mohammed, Hussein, Mohamed, Elkheshen, Ahmed, Patel, Vihang, Ali, Saad Emhmed, Lamb, Latoya, Ingram, Karen, Mayne, Casie, Stuffelbeam, Amy B., Flomenhoft, Deborah, Stromberg, Arnold, Barrett, Terrence A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576911/ https://www.ncbi.nlm.nih.gov/pubmed/33133239 http://dx.doi.org/10.1177/1756284820959245

Ejemplares similares

Asians Have Higher Risk of Developing Pancreatic Necrosis in Inflammatory Bowel Disease Patient Population: A National Inpatient Sample Database Study
por: Kudaravalli, Praneeth, et al.
Publicado: (2020)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

A challenging case of spontaneous bacterial empyema in a cirrhotic patient
por: Emhmed Ali, Saad, et al.
Publicado: (2019)

A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology
por: Soliman, Mohanad, et al.
Publicado: (2019)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Interstitial Granulomatous Drug Reaction to Ustekinumab
por: Walker, A., et al.
Publicado: (2022)

Ustekinumab-induced fixed drug eruption
por: Hafez, Dhafer M., et al.
Publicado: (2020)

Expanding beyond endoscopy: A review of non-invasive modalities in Barrett’s esophagus screening and surveillance
por: Shahsavari, Dariush, et al.
Publicado: (2022)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Ustekinumab-associated disseminated verrucae
por: Anderson, Mary E., et al.
Publicado: (2018)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Bullous pemphigoid during ustekinumab therapy
por: Le Guern, Aurore, et al.
Publicado: (2015)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Ustekinumab-induced subacute cutaneous lupus
por: Tierney, Emma, et al.
Publicado: (2019)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

A case of ustekinumab-induced sclerouveitis
por: Godwin, Kristen S., et al.
Publicado: (2022)

Bullous Wells Syndrome Induced by Ustekinumab
por: Kim, Yeona, et al.
Publicado: (2023)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

2523 Noninvasive biomarkers for inflammatory bowel disease: Drawbacks and potential
por: Patel, Vihang, et al.
Publicado: (2018)

Treatment of recalcitrant disseminated ulcerative necrobiosis lipoidica with ustekinumab
por: McMullan, Patrick, et al.
Publicado: (2023)

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings
por: Ramos-Leví, Ana M., et al.
Publicado: (2018)

Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report
por: Vallerand, Isabelle A, et al.
Publicado: (2019)

Stelara struck: a case of noninfectious pneumonitis secondary to ustekinumab
por: Despotes, Katherine A., et al.
Publicado: (2022)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab
por: Rakotonarivo, Louva, et al.
Publicado: (2018)

Morphea in a patient undergoing treatment with ustekinumab
por: Steuer, Alexa B., et al.
Publicado: (2019)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Refractory Autoimmune Enteropathy With Ustekinumab
por: Scheid, Johannes F., et al.
Publicado: (2021)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Assessing the Use of Ustekinumab in a Pediatric Patient With Harlequin Ichthyosis
por: Almuhanna, Nouf, et al.
Publicado: (2023)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_46ghsh5vpl3bdtq9d6pgokhg9i